Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer

◆ TRIAL DATA

A phase 1/2 trial testing copanlisib (a PIK3CA inhibitor) combined with nivolumab in metastatic microsatellite stable CRC did not meet its primary endpoint, with 0 of 17 PIK3CA-wildtype patients and 2 of 22 PIK3CA-mutant patients achieving a 6-month treatment response. (Nature Communications)